# Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)

> **NCT03019419** · PHASE2 · COMPLETED · sponsor: **Tokyo Medical University** · enrollment: 66 (actual)

## Conditions studied

- ALS

## Interventions

- **DRUG:** Perampanel
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03019419
- **Lead sponsor:** Tokyo Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-24
- **Primary completion:** 2020-12-23
- **Final completion:** 2020-12-23
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2021-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03019419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03019419, "Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03019419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*